REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

HIV patients are known to have up to a two-fold increase in heart-related events, compared with the general population. Could treatment with statins reduce this risk?

Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester, reviews the recently published results of the REPRIEVE trial. The big picture is a 35% reduction in heart-related events. Dr. Fine digs into the details and statistics of the trial, and the encouraging results of statin treatment, even in those deemed to be at lower risk. Related Content:

Jaksot(58)

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
voi-hyvin-meditaatiot-2
psykopodiaa-podcast
adhd-podi
rss-narsisti
psykologia
kesken
rss-vapaudu-voimaasi
rahapuhetta
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-duodecim-lehti
rss-valo-minussa-2
rss-luonnollinen-synnytys-podcast
rss-tietoinen-yhteys-podcast-2
aamukahvilla
rss-uskonto-on-tylsaa
rss-honest-talk-with-laurrenna
nakokulmia-rikollisuudesta-irrottautumiseen
rss-ai-mita-siskopodcast